DNA Origami Vaccine (DoriVac) Nanoparticles Improve Both Humoral and Cellular Immune Responses to Infectious Diseases

Authors
Zeng, Yang ClaireYoung, OliviaXiong, QianchengSi, LonglongKu, Min WenBernier, SylvieDembele, HawaIsinelli, GiorgiaGilboa, TalSwank, ZoeSeok, Su HyunRajwar, AnjaliJiang, AmandaZhai, YunhaoHellman, CalebWintersinger, ChrisGraveline, AmandaWilliams, LaTonyaVernet, AndynaSanchez, MelindaBardales, SaraiTomaras, GeorgiaRyu, Ju HeeKwon, Ick ChanGoyal, GirijaIngber, DonaldShih, William
Issue Date
2025-05
Publisher
Nature Publishing Group
Citation
Molecular Therapy, v.33, no.5
Abstract
Current SARS-CoV-2 vaccines have demonstrated robust induction of neutralizing antibodies and CD4+ T cell activation, however CD8+ responses are variable, and the duration of immunity and protection against variants are limited. Here we repurposed our DNA origami vaccine platform, DoriVac, for targeting infectious viruses, namely SARS-CoV-2, HIV, and Ebola. The DNA origami nanoparticle, conjugated with infectious-disease-specific HR2 peptides, which act as highly conserved antigens, and CpG adjuvant at precise nanoscale spacing, induced neutralizing antibodies, Th1 CD4+ T cells, and CD8+ T cells in na?ve mice, with significant improvement over a bolus control. Pre-clinical studies using lymph-node-on-a-chip systems validated that DoriVac, when conjugated with antigenic peptides or proteins, induced promising cellular immune responses in human cells. These results suggest that DoriVac holds potential as a versatile, modular vaccine platform, capable of inducing both humoral and cellular immunities. The programmability of this platform underscores its potential utility in addressing future pandemics.
ISSN
1525-0016
URI
https://pubs.kist.re.kr/handle/201004/152713
DOI
10.1101/2023.12.29.573647
Appears in Collections:
KIST Article > Others
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE